CN103189074A - 使用il-17拮抗剂治疗类风湿性关节炎的方法 - Google Patents

使用il-17拮抗剂治疗类风湿性关节炎的方法 Download PDF

Info

Publication number
CN103189074A
CN103189074A CN2011800529537A CN201180052953A CN103189074A CN 103189074 A CN103189074 A CN 103189074A CN 2011800529537 A CN2011800529537 A CN 2011800529537A CN 201180052953 A CN201180052953 A CN 201180052953A CN 103189074 A CN103189074 A CN 103189074A
Authority
CN
China
Prior art keywords
patient
antagonist
week
acpa
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800529537A
Other languages
English (en)
Chinese (zh)
Inventor
S·姆珀福
H·理查德斯
K·坦加维鲁
M·马哈切克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103189074(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN201510199026.8A priority Critical patent/CN104800844A/zh
Publication of CN103189074A publication Critical patent/CN103189074A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
CN2011800529537A 2010-11-05 2011-11-04 使用il-17拮抗剂治疗类风湿性关节炎的方法 Pending CN103189074A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510199026.8A CN104800844A (zh) 2010-11-05 2011-11-04 使用il-17拮抗剂治疗类风湿性关节炎的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41053310P 2010-11-05 2010-11-05
US61/410,533 2010-11-05
PCT/EP2011/069476 WO2012059598A2 (en) 2010-11-05 2011-11-04 Methods of treating rheumatoid arthritis using il-17 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510199026.8A Division CN104800844A (zh) 2010-11-05 2011-11-04 使用il-17拮抗剂治疗类风湿性关节炎的方法

Publications (1)

Publication Number Publication Date
CN103189074A true CN103189074A (zh) 2013-07-03

Family

ID=44906168

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510199026.8A Pending CN104800844A (zh) 2010-11-05 2011-11-04 使用il-17拮抗剂治疗类风湿性关节炎的方法
CN2011800529537A Pending CN103189074A (zh) 2010-11-05 2011-11-04 使用il-17拮抗剂治疗类风湿性关节炎的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510199026.8A Pending CN104800844A (zh) 2010-11-05 2011-11-04 使用il-17拮抗剂治疗类风湿性关节炎的方法

Country Status (30)

Country Link
US (10) US9744234B2 (enExample)
EP (6) EP4116325A1 (enExample)
JP (8) JP2014503482A (enExample)
KR (5) KR20180019247A (enExample)
CN (2) CN104800844A (enExample)
AU (1) AU2011325134B2 (enExample)
BR (1) BR112013011176A2 (enExample)
CA (2) CA2813849C (enExample)
CL (1) CL2013001213A1 (enExample)
CY (1) CY1121802T1 (enExample)
DE (1) DE20187001T1 (enExample)
DK (2) DK3111954T3 (enExample)
ES (3) ES2804624T1 (enExample)
FI (1) FI3757126T3 (enExample)
HR (2) HRP20251174T1 (enExample)
HU (1) HUE044038T2 (enExample)
IL (4) IL311014A (enExample)
LT (2) LT3757126T (enExample)
MA (1) MA34647B1 (enExample)
MX (1) MX362591B (enExample)
PH (1) PH12013500890A1 (enExample)
PL (1) PL3111954T3 (enExample)
PT (2) PT3757126T (enExample)
RS (1) RS67377B1 (enExample)
RU (1) RU2582937C2 (enExample)
SG (2) SG189138A1 (enExample)
SI (1) SI3111954T1 (enExample)
TR (1) TR201909531T4 (enExample)
TW (3) TWI604851B (enExample)
WO (1) WO2012059598A2 (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899231A (zh) * 2013-10-22 2016-08-24 诺夫免疫股份有限公司 用于在具有升高水平的tlr4配体和其它生物标记的患者中诊断和治疗病症的方法和组合物
CN106559985A (zh) * 2014-06-16 2017-04-05 埃博灵克斯股份有限公司 用免疫球蛋白单可变结构域治疗ttp的方法及其用途
CN107257692A (zh) * 2014-12-22 2017-10-17 诺华股份有限公司 Il‑17抗体的药物产品和稳定液体组合物
CN109641031A (zh) * 2016-08-23 2019-04-16 德国杰特贝林生物制品有限公司 预防与c1酯酶抑制剂缺乏相关的遗传性血管性水肿急性发作的方法
CN111511399A (zh) * 2017-11-23 2020-08-07 Ucb生物制药有限责任公司 制剂
CN112584857A (zh) * 2018-05-09 2021-03-30 诺华股份有限公司 卡那吉努单抗的用途
WO2021110164A1 (zh) * 2019-12-06 2021-06-10 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
CN113423401A (zh) * 2019-01-22 2021-09-21 豪夫迈·罗氏有限公司 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法
CN113825843A (zh) * 2019-05-17 2021-12-21 延世大学校产学协力团 提供抗癌免疫疗法治疗响应信息的方法及使用该方法的试剂盒
CN114306594A (zh) * 2021-12-21 2022-04-12 华中科技大学同济医学院附属协和医院 地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用
WO2022184114A1 (zh) * 2021-03-03 2022-09-09 苏州盛迪亚生物医药有限公司 抗il-17抗体治疗自身免疫性疾病和炎症的方法
CN115515610A (zh) * 2019-08-05 2022-12-23 伊夫罗生物科学公司 使用栖组织普雷沃菌治疗银屑病和特应性皮炎的组合物和方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
HUE044038T2 (hu) 2010-11-05 2019-09-30 Novartis Ag Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2013055745A2 (en) 2011-10-11 2013-04-18 Medimmune, Llc Cd40l-specific tn3-derived scaffolds and methods of use thereof
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
CN105916883B (zh) * 2014-01-28 2019-12-03 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
SMT201900544T1 (it) 2014-05-13 2019-11-13 Medimmune Ltd Anticorpi anti-b7-h1 e anti-ctla-4 per trattare il cancro del polmone non a piccole cellule
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2015258859B2 (en) 2014-05-15 2020-07-23 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
FR3021976B1 (fr) * 2014-06-06 2018-11-02 Hospices Civils De Lyon Marqueur biologique permettant d'evaluer le niveau pro-inflammatoire dependant de la contribution fonctionnelle de l'il-17 chez un individu
WO2015191760A2 (en) * 2014-06-10 2015-12-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
KR20230170796A (ko) * 2014-09-10 2023-12-19 노파르티스 아게 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
MX2017004983A (es) * 2014-10-22 2017-11-13 Armo Biosciences Inc Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
EP3265493B1 (en) 2015-03-02 2024-01-10 180 Therapeutics LP Method of treating a localized fibrotic disorder using an il-33 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
JP6858766B2 (ja) * 2015-10-19 2021-04-14 ノバルティス アーゲー インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
WO2019087133A1 (en) * 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
US20210340200A1 (en) * 2018-09-26 2021-11-04 Viela Bio, Inc. Cd40l antagonist and uses thereof
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
BR112022004941A2 (pt) * 2019-09-20 2022-06-28 Novartis Ag Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)
AU2020386669A1 (en) 2019-11-19 2022-06-02 Novartis Ag Methods of treating Lupus Nephritis using interleukin-17 (IL-17) antagonists
WO2021146850A1 (en) * 2020-01-20 2021-07-29 Tsinghua University A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4
WO2022113105A1 (en) * 2020-11-25 2022-06-02 Dr. Reddy's Laboratories Limited Stable therapeutic protein formulation and methods of making the same
TW202241505A (zh) * 2021-01-04 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
KR102339377B1 (ko) * 2021-03-29 2021-12-13 김지혜 사용자 맞춤형 문화 예술 컨텐츠 제공 방법 및 장치
KR20240024929A (ko) * 2021-06-21 2024-02-26 브리스톨-마이어스 스큅 컴퍼니 고농도 동결건조 생물제제 약물 제품의 재구성 시간을 감소시키기 위한 수크로스, 만니톨 및 글리신의 용도
WO2024156841A1 (en) 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
WO2025071335A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-17 항체의 안정한 액상 제형

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001645A (zh) * 2004-08-05 2007-07-18 诺瓦提斯公司 Il－17拮抗抗体

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US5250442A (en) * 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
JP4159682B2 (ja) 1998-12-22 2008-10-01 株式会社クラレ 止血材
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
MXPA04004459A (es) 2001-11-09 2005-05-16 Johnson & Johnson Composiciones liofilizadas de anticuerpo monoclonal.
WO2003073991A2 (en) 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US6974701B2 (en) 2003-03-21 2005-12-13 Hemovations, Llc Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8039642B2 (en) 2003-12-09 2011-10-18 Life Technologies Corporation Pyrenyloxysulfonic acid fluorescent agents
JP3936365B2 (ja) 2004-09-14 2007-06-27 ソニーケミカル＆インフォメーションデバイス株式会社 機能素子実装モジュール及びその製造方法
KR100996801B1 (ko) 2005-03-08 2010-11-25 파마시아 앤드 업존 캄파니 엘엘씨 항-ＭＡｄＣＡＭ 항체 조성물
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP1957474A4 (en) 2005-11-04 2011-08-24 Harvard College SYNTHESIS OF FTSZ HEMMERN
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
CN101374864A (zh) * 2006-01-31 2009-02-25 诺瓦提斯公司 用于靶向癌症的il-17拮抗性抗体
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
JP2010502220A (ja) 2006-09-05 2010-01-28 メダレックス インコーポレーティッド 骨形態形成タンパク質およびその受容体に対する抗体ならびにその使用方法
JPWO2008029908A1 (ja) 2006-09-07 2010-01-21 協和発酵キリン株式会社 抗体を含有する安定な凍結乾燥医薬製剤
UA99716C2 (ru) * 2006-10-02 2012-09-25 Кирин-Амген Инк. Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2008061013A2 (en) 2006-11-10 2008-05-22 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2094731A2 (en) 2006-11-10 2009-09-02 UCB Pharma S.A. Anti human sclerostin antibodies
NZ578235A (en) 2007-02-02 2012-05-25 Novartis Ag Modulators of sclerostin binding partners for treating bone-related disorders
RS53157B (sr) 2007-03-20 2014-06-30 Eli Lilly And Company Antitela na sklerostin
MX2009010179A (es) 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
WO2008121615A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
AU2008266745B2 (en) * 2007-06-20 2014-04-17 Merck Sharp & Dohme Corp. Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease
US7720605B2 (en) 2007-06-22 2010-05-18 Weyerhaeuser Nr Company Identifying vegetation attributes from LiDAR data
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EP2628486A3 (en) 2007-12-14 2013-10-30 Amgen, Inc. Method for treating bone fracture with anti-sclerostin antibodies
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20090301682A1 (en) 2008-06-05 2009-12-10 Baker Hughes Incorporated Casting furnace method and apparatus
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
UA103499C2 (ru) 2008-09-29 2013-10-25 Рош Глікарт Аг Антитело против интерлейкина-17 (ил-17) человека и его применение
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
FR2938547B1 (fr) 2008-11-14 2012-11-16 Total Raffinage Marketing Liant synthetique clair
WO2010065491A2 (en) 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
KR101579771B1 (ko) 2009-03-05 2015-12-28 애브비 인코포레이티드 Ｉｌ-17 결합 단백질
CN103154031A (zh) 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
HUE044038T2 (hu) 2010-11-05 2019-09-30 Novartis Ag Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával
TW201307845A (zh) * 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
AU2012341081B2 (en) 2011-11-21 2015-06-04 Novartis Ag Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
EP2838560A2 (en) 2012-04-20 2015-02-25 Novartis AG Methods of treating ankylosing spondylitis using il-17 antagonists
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
JP6858766B2 (ja) 2015-10-19 2021-04-14 ノバルティス アーゲー インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
US11280479B2 (en) 2017-10-18 2022-03-22 The Sloan Company Sign box light module

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001645A (zh) * 2004-08-05 2007-07-18 诺瓦提斯公司 Il－17拮抗抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WOLFGANG HUEBER ETAL: "Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis and Uveitis", 《SCIENCE TRANSLATION MEDICINE》 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899231A (zh) * 2013-10-22 2016-08-24 诺夫免疫股份有限公司 用于在具有升高水平的tlr4配体和其它生物标记的患者中诊断和治疗病症的方法和组合物
CN106559985A (zh) * 2014-06-16 2017-04-05 埃博灵克斯股份有限公司 用免疫球蛋白单可变结构域治疗ttp的方法及其用途
CN113876947A (zh) * 2014-12-22 2022-01-04 诺华股份有限公司 Il-17抗体的药物产品和稳定液体组合物
CN107257692A (zh) * 2014-12-22 2017-10-17 诺华股份有限公司 Il‑17抗体的药物产品和稳定液体组合物
US12485173B2 (en) 2014-12-22 2025-12-02 Novartis Ag Pharmaceutical products and stable liquid compositions of IL-17 antibodies
US12485172B2 (en) 2014-12-22 2025-12-02 Novartis Ag Pharmaceutical products and stable liquid compositions of IL-17 antibodies
CN114452380B (zh) * 2014-12-22 2025-10-17 诺华股份有限公司 Il-17抗体的药物产品和稳定液体组合物
CN107257692B (zh) * 2014-12-22 2021-11-19 诺华股份有限公司 Il-17抗体的药物产品和稳定液体组合物
CN114452380A (zh) * 2014-12-22 2022-05-10 诺华股份有限公司 Il-17抗体的药物产品和稳定液体组合物
CN113855800A (zh) * 2014-12-22 2021-12-31 诺华股份有限公司 Il-17抗体的药物产品和稳定液体组合物
CN109641031A (zh) * 2016-08-23 2019-04-16 德国杰特贝林生物制品有限公司 预防与c1酯酶抑制剂缺乏相关的遗传性血管性水肿急性发作的方法
CN111511399A (zh) * 2017-11-23 2020-08-07 Ucb生物制药有限责任公司 制剂
CN112584857A (zh) * 2018-05-09 2021-03-30 诺华股份有限公司 卡那吉努单抗的用途
CN113423401A (zh) * 2019-01-22 2021-09-21 豪夫迈·罗氏有限公司 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法
CN113825843A (zh) * 2019-05-17 2021-12-21 延世大学校产学协力团 提供抗癌免疫疗法治疗响应信息的方法及使用该方法的试剂盒
CN115515610A (zh) * 2019-08-05 2022-12-23 伊夫罗生物科学公司 使用栖组织普雷沃菌治疗银屑病和特应性皮炎的组合物和方法
WO2021110164A1 (zh) * 2019-12-06 2021-06-10 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
WO2022184114A1 (zh) * 2021-03-03 2022-09-09 苏州盛迪亚生物医药有限公司 抗il-17抗体治疗自身免疫性疾病和炎症的方法
CN114306594A (zh) * 2021-12-21 2022-04-12 华中科技大学同济医学院附属协和医院 地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用

Also Published As

Publication number Publication date
CN104800844A (zh) 2015-07-29
FI3757126T3 (fi) 2025-10-12
US11534491B2 (en) 2022-12-27
IL282625A (en) 2021-06-30
SG10201505624VA (en) 2015-09-29
HRP20191162T1 (hr) 2019-10-04
MX362591B (es) 2019-01-25
EP3111954A1 (en) 2017-01-04
EP3757126A1 (en) 2020-12-30
BR112013011176A2 (pt) 2020-09-01
IL225309A0 (en) 2013-06-27
JP6515168B2 (ja) 2019-05-15
HRP20251174T1 (hr) 2025-11-21
JP6250109B2 (ja) 2017-12-20
US20250205332A1 (en) 2025-06-26
KR20140008305A (ko) 2014-01-21
EP3111954B1 (en) 2019-04-03
JP6049843B2 (ja) 2016-12-21
EP3757126B1 (en) 2025-09-03
US20210177966A1 (en) 2021-06-17
WO2012059598A3 (en) 2012-09-27
US20220193234A1 (en) 2022-06-23
ES2733712T3 (es) 2019-12-02
KR20180019247A (ko) 2018-02-23
EP4116325A1 (en) 2023-01-11
IL225309B (en) 2021-05-31
JP2021104995A (ja) 2021-07-26
US10363307B2 (en) 2019-07-30
PT3111954T (pt) 2019-07-10
TW201517917A (zh) 2015-05-16
KR20150020734A (ko) 2015-02-26
SG189138A1 (en) 2013-05-31
CA3116725A1 (en) 2012-05-10
PL3111954T3 (pl) 2019-10-31
TWI616204B (zh) 2018-03-01
TWI604851B (zh) 2017-11-11
CA3116725C (en) 2023-10-24
US9744234B2 (en) 2017-08-29
US20230346926A1 (en) 2023-11-02
CY1121802T1 (el) 2020-07-31
US20200276305A1 (en) 2020-09-03
AU2011325134B2 (en) 2014-10-23
CA2813849A1 (en) 2012-05-10
EP3912640A1 (en) 2021-11-24
DE20187001T1 (de) 2021-04-01
MX2013005060A (es) 2013-06-28
KR20160067984A (ko) 2016-06-14
TWI618543B (zh) 2018-03-21
RU2582937C2 (ru) 2016-04-27
TW201726170A (zh) 2017-08-01
JP2017002064A (ja) 2017-01-05
JP2019142912A (ja) 2019-08-29
ES2804624T1 (es) 2021-02-08
DK3757126T3 (da) 2025-09-29
IL311014A (en) 2024-04-01
JP2018065826A (ja) 2018-04-26
EP2635303A2 (en) 2013-09-11
JP2016065094A (ja) 2016-04-28
IL262559B (en) 2022-06-01
US20180008706A1 (en) 2018-01-11
CA2813849C (en) 2021-06-15
SI3111954T1 (sl) 2019-08-30
JP2025102772A (ja) 2025-07-08
CL2013001213A1 (es) 2014-03-28
PT3757126T (pt) 2025-11-13
RU2013125775A (ru) 2014-12-10
JP2023109910A (ja) 2023-08-08
ES3030036T3 (en) 2025-06-26
TW201306864A (zh) 2013-02-16
US20130209480A1 (en) 2013-08-15
US12465635B2 (en) 2025-11-11
WO2012059598A2 (en) 2012-05-10
RS67377B1 (sr) 2025-11-28
LT3757126T (lt) 2025-12-10
HUE044038T2 (hu) 2019-09-30
TR201909531T4 (tr) 2019-07-22
US20230293683A1 (en) 2023-09-21
EP3542820A1 (en) 2019-09-25
JP2014503482A (ja) 2014-02-13
IL262559A (en) 2018-12-31
KR20180129991A (ko) 2018-12-05
PH12013500890A1 (en) 2013-07-01
LT3111954T (lt) 2019-07-10
US20210128726A1 (en) 2021-05-06
MA34647B1 (fr) 2013-11-02
AU2011325134A1 (en) 2013-04-04
EP3912640B1 (en) 2025-03-05
US20190307880A1 (en) 2019-10-10
DK3111954T3 (da) 2019-07-15

Similar Documents

Publication Publication Date Title
US12465635B2 (en) Methods of treating inflammatory arthritis using secukinumab
HK40010039A (en) Methods of treating psoriatic arthritis using il-17 antagonists
HK40035240A (en) Methods of treating psoriatic arthritis using il-17 antagonists
HK40040628A (en) Methods of treating psoriatic arthritis using il-17 antagonists
HK40061520A (en) Pharmaceutical compositions comprising secukinumab
HK40083901A (en) Methods of treating rheumatoid arthritis using il-17 antagonists
HK1229257B (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies
HK1229257A1 (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130703